Healthcare stocks were advancing premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) 0.6% higher.
Sionna Therapeutics (SION) shares were down more than 5% after the company reported a wider-than-expected Q1 net loss.
Alkermes (ALKS) said a late-stage trial evaluating its investigational Lumryz oral suspension in adults with idiopathic hypersomnia, a rare condition in which patients require excessive sleep, met all primary and key secondary endpoints. Alkermes stock was up more than 2% pre-bell.
BridgeBio Pharma (BBIO) shares were up more than 1% after the company said it has submitted a new drug application to the US Food and Drug Administration for encaleret, a potential treatment for autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic condition affecting calcium levels.